JP2025511122A5 - - Google Patents

Info

Publication number
JP2025511122A5
JP2025511122A5 JP2024557915A JP2024557915A JP2025511122A5 JP 2025511122 A5 JP2025511122 A5 JP 2025511122A5 JP 2024557915 A JP2024557915 A JP 2024557915A JP 2024557915 A JP2024557915 A JP 2024557915A JP 2025511122 A5 JP2025511122 A5 JP 2025511122A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
cancer
optionally substituted
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024557915A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511122A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/064984 external-priority patent/WO2023192817A1/en
Publication of JP2025511122A publication Critical patent/JP2025511122A/ja
Publication of JP2025511122A5 publication Critical patent/JP2025511122A5/ja
Pending legal-status Critical Current

Links

JP2024557915A 2022-03-28 2023-03-27 リジンアセチルトランスフェラーゼのmystファミリーの阻害剤 Pending JP2025511122A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263324624P 2022-03-28 2022-03-28
US202263324619P 2022-03-28 2022-03-28
US63/324,624 2022-03-28
US63/324,619 2022-03-28
US202263476826P 2022-12-22 2022-12-22
US63/476,826 2022-12-22
PCT/US2023/064984 WO2023192817A1 (en) 2022-03-28 2023-03-27 Inhibitors of the myst family of lysine acetyl transferases

Publications (2)

Publication Number Publication Date
JP2025511122A JP2025511122A (ja) 2025-04-15
JP2025511122A5 true JP2025511122A5 (enExample) 2026-04-06

Family

ID=86099757

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024557915A Pending JP2025511122A (ja) 2022-03-28 2023-03-27 リジンアセチルトランスフェラーゼのmystファミリーの阻害剤

Country Status (11)

Country Link
US (3) US12187732B2 (enExample)
EP (1) EP4499609A1 (enExample)
JP (1) JP2025511122A (enExample)
KR (1) KR20250006833A (enExample)
CN (1) CN119301096A (enExample)
AU (1) AU2023241822A1 (enExample)
CA (1) CA3255313A1 (enExample)
IL (1) IL315930A (enExample)
MX (1) MX2024011828A (enExample)
TW (1) TW202400593A (enExample)
WO (1) WO2023192817A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023088233A1 (en) 2021-11-16 2023-05-25 Insilico Medicine Ip Limited Lysine acetyltransferase 6a (kat6a) inhibitors and uses thereof
AU2023241822A1 (en) * 2022-03-28 2024-09-26 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
WO2024199254A1 (zh) * 2023-03-27 2024-10-03 北京康辰药业股份有限公司 磺酰胺化合物、其药物组合物和应用
AU2024325442A1 (en) * 2023-08-14 2026-03-26 Shanghai Henlius Biologics Co., Ltd. Sulfonamide compound, and preparation method therefor and use thereof
IL327069A (en) * 2023-09-27 2026-05-01 Isosterix Inc Mist inhibitors
WO2025098417A1 (zh) * 2023-11-08 2025-05-15 再和医药科技(苏州)有限公司 磺酰胺类化合物及其应用
WO2026053122A1 (en) * 2024-09-04 2026-03-12 Dana-Farber Cancer Institute, Inc. Methods of treating retinoid responsive cancers
EP4741375A1 (en) * 2024-11-06 2026-05-13 Qubit Pharmaceuticals Sulfonylurea derivatives and their use for the treatment of cancer

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
WO1997001331A2 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
ZA9711385B (en) 1996-12-20 1999-06-18 Takeda Chemical Industries Ltd Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU2017373758B2 (en) 2016-12-07 2021-12-16 Orimos Therapeutics Co., Ltd. Compounds and pharmaceutical compositions for modulating SGK activity, and methods thereof
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
PH12021553107A1 (en) * 2019-06-18 2022-08-01 Ctxt Pty Ltd Benzisoxazole sulfonamide derivatives
AU2020295006B2 (en) 2019-06-19 2023-11-09 Ctxt Pty Ltd Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives
PT4181920T (pt) 2020-07-15 2025-11-04 Ctxt Pty Ltd Inibidor de kat6 e combinações para o tratamento do cancro da mama
EP4229048A4 (en) 2020-10-16 2024-11-20 The Broad Institute, Inc. Substituted acyl sulfonamides for treating cancer
EP4229045B1 (en) 2020-10-16 2025-11-12 The Broad Institute Inc. Substituted acyl sulfonamides for treating cancer
US20240254139A1 (en) 2021-05-21 2024-08-01 Aurigene Oncology Limited Fused isoxazolyl compounds as kat6a inhibitors
CN118382622A (zh) 2021-07-05 2024-07-23 杭州英创医药科技有限公司 作为kat6抑制剂的化合物
CN115594695A (zh) 2021-07-09 2023-01-13 江苏恒瑞医药股份有限公司(Cn) 大环类化合物、其制备方法及其在医药上的应用
CN115611877A (zh) 2021-07-12 2023-01-17 江苏恒瑞医药股份有限公司 磺酰胺类化合物、其制备方法及其在医药上的应用
WO2023014867A1 (en) 2021-08-05 2023-02-09 Google Llc Managing paging for multicast and broadcast services
JP2024529068A (ja) 2021-08-10 2024-08-01 江蘇恒瑞医薬股▲ふん▼有限公司 スルファミド誘導体、その調製方法及びその医薬的使用
WO2023088233A1 (en) 2021-11-16 2023-05-25 Insilico Medicine Ip Limited Lysine acetyltransferase 6a (kat6a) inhibitors and uses thereof
CA3241874A1 (en) 2021-12-13 2023-06-22 Aurigene Oncology Limited Fused benzoisoxazolyl compounds as kat6a inhibitors
WO2023114867A2 (en) 2021-12-15 2023-06-22 Dana-Farber Cancer Institute, Inc. Therapeutic targeting of gastrointestinal stromal tumor (gist) by disrupting the menin-mll epigenetic complex
AU2023241822A1 (en) * 2022-03-28 2024-09-26 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
CN115073392B (zh) 2022-05-30 2023-09-12 中美(河南)荷美尔肿瘤研究院 N,n-二乙基磺酰胺二取代的苯并噻唑类衍生物、其制备方法及应用

Similar Documents

Publication Publication Date Title
JP7536064B2 (ja) 抗癌活性及び抗増殖活性を呈する2-アミノピリミジン-6-オン及び類似体
JP2021507900A5 (enExample)
JP2021508686A5 (enExample)
TWI877136B (zh) 化合物、組合物及方法
RU2472797C2 (ru) ПРОИЗВОДНЫЕ 2-[(2-(ФЕНИЛАМИНО)-1Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АМИНО]БЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IGF-1R ДЛЯ ЛЕЧЕНИЯ РАКА
JP2019031560A5 (enExample)
JP2013056930A5 (enExample)
JP6173426B2 (ja) アミノ置換イミダゾピリダジン
CN114174303B (zh) 作为sting激动剂的大环化合物及其方法和用途
RU2020123151A (ru) Антагонисты tlr7/8 и их применение
RU2016115868A (ru) Замещенные гетероциклические сульфонамидные соединения, полезные в качестве модуляторов trpa 1
JP2014513704A5 (enExample)
CA3293479A1 (en) Bicyclic urea kinase inhibitors and uses thereof
CN110573500A (zh) N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用
JP2020517616A5 (enExample)
RU2012131416A (ru) Ингибиторы фосфатидилинозитол-3-киназы на основе изоиндолинона
JP2019518766A5 (enExample)
RU2018102372A (ru) Новые аминокислотные производные, способ их получения и фармацевтические композиции, содержащие их
JP2016523973A5 (enExample)
JP2015503625A5 (enExample)
JP2016532673A5 (enExample)
RU2014118677A (ru) Ингибиторы киназ типа polo
RU2014136339A (ru) Замещенные пролины/пиперидины как антагонисты орексиновых рецепторов
RU2013154412A (ru) Аминопиримидины в качестве ингибиторов syc
RU2016141647A (ru) ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ